RxDoctor Payments Data

Margaret Terhune, MD

Dermatology · Richmond, VANPI 1720008246

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 744 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations.

$13,428in general payments, 2019–2025

Across 744 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • UCB, Inc.$1K
  • Pfizer$1K
  • Amgen$849
  • Sun Pharmaceutical Industries Inc.$749
  • plus $6K from 29 others

What the payments were for

  • Food & beverage$13,24599%
  • Education$1831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,428 in reported general payments places this provider in the 85th percentile of 396 dermatology providers in Virginia.

See all dermatology providers in Virginia

Medicare billing

Part B allowed, 2024
$462,120
Medicare patients
1,794
Services billed
6,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast15$68,261
Doxycycline Hyclate182$7,489
Fluorouracil85$6,837
Clobetasol Propionate91$5,915
Betamethasone Dipropionate164$5,320
Metronidazole78$4,552
Ketoconazole193$3,697
Fluocinonide80$3,505
Tacrolimus11$2,621
Triamcinolone Acetonide250$2,135
Acitretin11$1,570
Tretinoin18$1,492
Ciclopirox26$750
Clindamycin Phosphate20$691
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet17$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$849$68,26115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 396 dermatology providers in Virginia.

Other dermatology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →